Evidence map›Paper›PMID 38951814›Full record

ArticleVirology journal2024

Differences in neutralizing antibody sensitivities and envelope characteristics indicate distinct antigenic properties of Nigerian HIV-1 subtype G and CRF02_AG.

Lindsay Wieczorek, David Chang, Eric Sanders-Buell, Michelle Zemil, Elizabeth Martinez, Jesse Schoen, Agnes-Laurence Chenine, Sebastian Molnar, Brittani Barrows, Kultida Poltavee and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virology journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Lindsay WieczorekU.S. Military HIV Research Program, CIDR, Walter Reed Army Institute of Resarch, Silver Spring, MD, USA.
David ChangU.S. Military HIV Research Program, CIDR, Walter Reed Army Institute of Resarch, Silver Spring, MD, USA.
Eric Sanders-BuellU.S. Military HIV Research Program, CIDR, Walter Reed Army Institute of Resarch, Silver Spring, MD, USA.
Michelle ZemilU.S. Military HIV Research Program, CIDR, Walter Reed Army Institute of Resarch, Silver Spring, MD, USA.
Elizabeth MartinezU.S. Military HIV Research Program, CIDR, Walter Reed Army Institute of Resarch, Silver Spring, MD, USA.
Jesse SchoenU.S. Military HIV Research Program, CIDR, Walter Reed Army Institute of Resarch, Silver Spring, MD, USA.
Agnes-Laurence ChenineU.S. Military HIV Research Program, CIDR, Walter Reed Army Institute of Resarch, Silver Spring, MD, USA.
Sebastian MolnarU.S. Military HIV Research Program, CIDR, Walter Reed Army Institute of Resarch, Silver Spring, MD, USA.
Brittani BarrowsU.S. Military HIV Research Program, CIDR, Walter Reed Army Institute of Resarch, Silver Spring, MD, USA.
Kultida PoltaveeSEARCH, Insititute of HIV Research and Innovation (IHRI), Bangkok, Thailand.
Man E CharuratInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
Alash'le AbimikuInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
William BlattnerInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
Michael IroezinduU.S. Military HIV Research Program, CIDR, Walter Reed Army Institute of Resarch, Silver Spring, MD, USA.
Afoke KokoghoU.S. Military HIV Research Program, CIDR, Walter Reed Army Institute of Resarch, Silver Spring, MD, USA.
Nelson L MichaelCenter for Infectious Disease Research, Walter Reed Army Institute of Resarch, Silver Spring, MD, USA.
Trevor A CrowellU.S. Military HIV Research Program, CIDR, Walter Reed Army Institute of Resarch, Silver Spring, MD, USA.
Julie A AkeU.S. Military HIV Research Program, CIDR, Walter Reed Army Institute of Resarch, Silver Spring, MD, USA.
Sodsai TovanabutraU.S. Military HIV Research Program, CIDR, Walter Reed Army Institute of Resarch, Silver Spring, MD, USA.
Victoria R PolonisU.S. Military HIV Research Program, CIDR, Walter Reed Army Institute of Resarch, Silver Spring, MD, USA. vpolonis@hivresearch.org.
AFRICOS and TRUST/RV368 Study Groups

Funding

Validation of Stigma Metrics for Marginalized Men R01MH110358 · NIMH · JOHNS HOPKINS UNIVERSITY · PI BARAL, STEFAN DAVID · 2017 to 2021
$3.6M
Building TRUSTR01AI120913 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI CHARURAT, MANHATTAN E · 2015 to 2019
$3.3M
TRUSTR01MH099001 · NIMH · UNIVERSITY OF MARYLAND BALTIMORE · PI CHARURAT, MANHATTAN E · 2012 to 2014
$2.9M
Epidemiology Research Training for Public Health Impact in Nigeria (Epi-Nigeria)D43TW010051 · FIC · UNIVERSITY OF MARYLAND BALTIMORE · PI ABIMIKU, ALASH'LE G., CHARURAT, MANHATTAN E · 2016 to 2020
$1.5M
FIC NIH HHS D43 TW010051Fogarty Epidemiology Research Training for Public Health Impact in Nigeria program D43TW010051NIAID NIH HHS R01 AI120913NIH HHS R01 MH099001, R01 AI120913, R01 MH110358NIMH NIH HHS R01 MH099001NIMH NIH HHS R01 MH110358U.S. Department of Defense W81XWH-11-2-0174, W81XWH-07-2-0067, W81XWH-18-2-0040U.S. President's Emergency Plan for AIDS Relief NU2GGH002099
6 · The paper itself

Abstract

The magnitude of the HIV-1 epidemic in Nigeria is second only to the subtype C epidemic in South Africa, yet the subtypes prevalent in Nigeria require further characterization. A panel of 50 subtype G and 18 CRF02_AG Nigerian HIV-1 pseudoviruses (PSV) was developed and envelope coreceptor usage, neutralization sensitivity and cross-clade reactivity were characterized. These PSV were neutralized by some antibodies targeting major neutralizing determinants, but potentially important differences were observed in specific sensitivities (eg. to sCD4, MPER and V2/V3 monoclonal antibodies), as well as in properties such as variable loop lengths, number of potential N-linked glycans and charge, demonstrating distinct antigenic characteristics of CRF02_AG and subtype G. There was preferential neutralization of the matched CRF/subtype when PSV from subtype G or CRF02_AG were tested using pooled plasma. These novel Nigerian PSV will be useful to study HIV-1 CRF- or subtype-specific humoral immune responses for subtype G and CRF02_AG.

Indexed as

Antibodies, NeutralizingHIV-1HIV AntibodiesHIV InfectionsNeutralization TestsCross Reactionsenv Gene Products, Human Immunodeficiency VirusHumansNigeriaAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusHIV AntibodiesAntibodyCRF02_AGEnvelope (Env)HIVNeutralizationNigeriaSubtype GWest Africa

Identifiers

PMID38951814
PMCPMC11218331

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.